What if the best cancer treatment for you can’t be mass-produced? What if the drug, dose, pathway targets, and delivery route all have to be custom-designed from the ground up — not because it's luxurious, but because it’s necessary?
In this episode of Outsmart Cancer, Dr. Dino Prato explains why true precision oncology is fundamentally different from standard cancer care. Inspired by the St. Jude model for rare pediatric cancers, Dr. Prato reveals why adults with heterogeneous tumors also need custom-built therapies created from DNA sequencing, RNA transcriptomics, immune spatial biology, and real-time monitoring.
Instead of relying on one-size-fits-all guidelines and limited FDA-approved drugs, N-of-1 oncology builds a personalized playbook using on-label, off-label, repurposed drugs, phytotherapeutics, and cellular biologics — all designed around each patient’s unique molecular drivers. This ecosystem includes custom drug compounding, microdosed combination therapy, direct-to-tumor delivery, and immune rebuilding through NK and dendritic cell biologics.
🎯 What You’ll Learn in This Episode:
• Why standard care cannot treat today’s heterogeneous, complex cancers
• How St. Jude’s precision model inspired Envita’s N-of-1 adult ecosystem
• How DNA, RNA, and spatial biology testing reveal thousands of unique targets
• Why custom-built drugs and phytotherapeutics outperform off-the-shelf options
• How cellular biologics (NK & dendritic cells) rebuild immune killing
• Why direct-to-tumor delivery beats systemic chemotherapy for many patients
• What real-time monitoring (CTCs, methylation, ctDNA) reveals long before imaging
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493
